Biosion, Inc. ("Biosion"), a global, clinical-stage biotechnology company developing innovative antibody-based therapeutics, today announced that the first patient has been dosed in a Phase 1a/1b ...
CD47 expression levels may predict evorpacept efficacy in HER2-positive metastatic breast cancer, especially in heavily pretreated patients. Evorpacept combined with zanidatamab shows promising ...
HCB301 is a first-in-class tri-specific immunotherapy targeting SIRPα-CD47, PD-1/PD-L1, and TGFβ; it shows potent macrophage activation, T-cell restoration, and tumor microenvironment remodeling in ...
Prestigious peer-review validates HCB101's differentiated mechanism and translational strength. Clinical data show a nearly 90% partial response rate in 2L gastric cancer (combo) and safe escalation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results